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Optimized Antimicrobial Dosing Strategies: A Survey of Pediatric Hospitals 
Chad A. Knoderer  
Kristen R. Nichols 
Elaine G. Cox 
Abstract: 
Background 
Extended-interval aminoglycoside (EIAG) and extended- and continuous-infusion β-lactam (EIBL and 
CIBL) dosing strategies are increasingly used in adults, but pediatric literature is limited. 
Objective 
The objective of this study was to describe the use of EIAG, EIBL, and CIBL dosing in pediatric 
hospitals in the USA. 
Study Design, Setting, and Participants 
A national survey of children’s hospitals was conducted. A single practitioner from each target hospital 
was identified through the Children’s Hospital Association. Practice-based survey questions identified 
whether hospitals utilize EIAG, EIBL, and CIBL dosing. 
Main Outcome Measure 
The main outcome measure was the percentage utilization of the dosing strategies, with secondary 
outcomes being the reasons for not using these dosing strategies. 
Results 
Seventy-seven of 215 identified practitioners (36 %) participated in the survey. EIAG, EIBL, and CIBL 
dosing were utilized in 63 %, 24 %, and 13 % of responding hospitals, respectively. The most common 
reasons for not using EIAG were concern regarding lack of efficacy data (56 %) and concern regarding 
the duration of the drug-free period (41 %). Respondents who did not utilize EIBL cited concern due to 
lack of pediatric EIBL efficacy data (54 %), the need for more intravenous access (54 %), intravenous 
medication compatibility issues (39 %), and the time during which the patient is attached to an 
intravenous infusion (31 %). 
Conclusion 
This survey of children’s hospitals indicates that EIAG is used in over 50 % of hospitals, but there is 
some lag in adoption of EIBL and CIBL dosing, both of which are used in fewer than 25 % of hospitals. 
Additional studies may provide much-needed evidence to increase the utilization of these strategies. 
 
 
 
 
2 
 
 
1 Introduction 
Judicious and optimal antimicrobial use in children has become increasingly important in light of 
emerging bacterial resistance and its association with poor patient outcomes [1, 2]. Optimal 
antimicrobial utilization includes employing dosing strategies designed to enhance the drugs’ 
pharmacokinetic and pharmacodynamic properties for the most effective dosing regimen [3]. 
Dosing strategies such as extended-interval aminoglycoside (EIAG) and extended- and 
continuous-infusion β-lactam (EIBL and CIBL) have been well described in adults [4–7]. A 
complete review of experience with these dosing strategies in adults is beyond the scope of this 
report. While adoption of these dosing strategies has become increasingly common in the adult 
population, there remain limited data in children regarding efficacy, safety, and prevalence [8–14]. 
 
Pediatric EIAG use has been well described, but definitive safety and efficacy data, in comparison 
with conventional aminoglycoside dosing, are not widely available. The prevalence of EIAG in 
practice is not widely known. Prescott found that once-daily aminoglycoside dosing is used in 
nearly 85 % of programs caring for patients with cystic fibrosis exacerbations [15]. In a survey of 
500 acute care hospitals, Chuck and colleagues found that EIAG dosing specifically for pediatrics 
was used in 23 % of responding hospitals [16]. Extended-infusion piperacillin–tazobactam (EIPT) 
has been described in one pediatric cohort, which demonstrated the feasibility of the dosing 
strategy [10]. Courter and colleagues demonstrated with Monte Carlo simulation the enhanced 
probability of target attainment with EIPT and extended-infusion cefepime (EIC) [13]. A 2014 
study, utilizing pediatric serum concentration data, also demonstrated increased probability of 
target attainment using EIPT strategies [14]. Despite this, there are very few data describing EIBL 
in children. The prevalence of use of these optimized dosing strategies in children remains largely 
unknown. 
 
Continual assessment and quality improvement of institutional antimicrobial utilization is an 
important component of an antimicrobial stewardship program (ASP). The goal of assessing the 
current use of EIAG, EIBL, and CIBL dosing in the USA is to identify and promote safe and 
optimal utilization of these antimicrobials. The objective of this study was to determine the 
prevalence of use of EIAG, EIBL, and CIBL dosing in pediatric hospitals in the USA, and to 
determine barriers to using the strategies in practice. 
2 Methods 
This was a national survey of hospitals providing acute care for children, and was approved by the 
Butler University Institutional Review Board. Target hospitals were chosen by identification of 
members of the Children’s Hospital Association (CHA). A single practitioner from each hospital 
was identified as the survey contact through a search of the American College of Clinical 
Pharmacy Practice and Research Networks for Pediatrics and Infectious Diseases, the American 
Society of Health System Pharmacists Online Residency Directory, the CHA Directors of Quality 
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list, a contact list provided at the 4th Annual International Pediatric Antimicrobial Stewardship 
Conference in Kansas City (MO, USA), or from information provided by the hospital via telephone 
in response to direct requests by the researchers. The practitioner contact’s e-mail address was 
obtained through this search and utilized for survey distribution. 
The survey questions focused on demographics, antimicrobial stewardship practices, 
aminoglycoside dosing practices, and β-lactam dosing practices. Conditional logic was 
incorporated, and respondents could answer a maximum of 25 questions. Demographic and 
antimicrobial stewardship questions assessed the presence of an ASP, pharmacokinetic consult 
services, antimicrobial order guidance, hospital size, and geographic location. Practice-based 
survey questions identified whether hospitals are utilizing EIAG, EIBL, and CIBL dosing 
strategies, as well as reasons cited for not using these dosing strategies. Open-ended text boxes 
were utilized to capture additional reasons for not utilizing a particular dosing strategy. 
The survey was conducted through SurveyMonkey (Palo Alto, CA, USA). A survey link was e-
mailed, along with a cover letter invitation and survey description, to the identified practitioners 
at each hospital on January 15, 2014. Practitioners received follow-up e-mail reminders to 
complete the survey at weeks 2 and 4, and the survey remained open for a total of 6 weeks. 
2.1 Data Analysis 
Descriptive statistics were utilized to characterize respondent demographics. Analysis of the 
nonparametric correlations between demographic characteristics and the use of EIAG, EIBL, and 
CIBL was performed using χ2 analysis and Spearman’s rank order correlation. P values of less 
than 0.05 were considered to be statistically significant. Statistical analyses were conducted using 
Statistical Package for Social Sciences version 19.0 (SPSS, Inc., Chicago, IL, USA). 
3 Results 
A total of 236 hospitals were identified through the CHA. Practitioners with e-mail contact 
information were identified for 221 of these. The initial survey e-mail was undeliverable for five 
of these contacts, and one practitioner was subsequently identified as being unaffiliated with a 
pediatric hospital, yielding a final sample of 215 hospitals. Seventy-seven practitioners completed 
the survey, for a 36 % response rate. 
Survey respondents were primarily clinical pharmacists (79.2 %) and prescribers (13 %). Hospitals 
were described primarily as non-profit (84.4 %) and teaching hospitals (93.5 %). The majority of 
hospitals were free-standing children’s hospitals (46.8 %) or a children’s hospital within an adult 
hospital (48.1 %), and 51.9 % (40/77) contained 100–200 beds. Hospitals were equally distributed 
across geographic regions. ASPs were present in 72.5 % of hospitals (56/77), and 57 % of those 
programs had at least one full-time employee (FTE) dedicated to the program. Pharmacokinetic 
consult services and written antimicrobial order guidance were available in 74 % of hospitals 
(57/77) and in 80.5 % of hospitals (62/77), respectively. Demographic responses are summarized 
in Table 1. 
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Table 1  
Demographic characteristics 
Characteristic [N = 77] n (%) 
Position of survey respondent 
 Clinical pharmacist 61 (79.2) 
 Physician: infectious diseases specialist 6 (7.8) 
 Other pharmacist 6 (7.8) 
 Medical doctor 2 (2.6) 
 Nurse practitioner 2 (2.6) 
Hospital description 
 Free-standing children’s hospital 36 (46.8) 
 Children’s hospital within an adult hospital 37 (48.1) 
 Children’s ward within an adult hospital 3 (3.9) 
 Adult hospital that cares for children [no specific children’s unit] 1 (1.3) 
Hospital size 
 <100 beds 7 (9.1) 
 100–200 beds 13 (16.9) 
 201–500 beds 40 (51.9) 
 501–800 beds 11 (14.3) 
 >800 beds 6 (7.8) 
Geographic region 
 Northeast 18 (23.4) 
 Southeast 18 (23.4) 
 Midwest 19 (24.6) 
 West 12 (15.6) 
 Southwest 10 (13.0) 
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3.1 Extended-Interval Aminoglycoside Dosing 
Forty-seven of 75 responding practitioners (62.7 %) stated that EIAG dosing was used within their 
hospital, with 57.4 % of those respondents (27/47) indicating use all or most of the time for 
aminoglycoside dosing. There were no significant relationships observed between EIAG and 
presence of an ASP (r s = 0.158), ASP FTE ≥1 (r s = 0.026), teaching hospital (r s = −0.096), 
region (r s = −0.184), or free-standing children’s hospital (r s = −0.107). A fair positive and 
significant relationship was observed between total bed number and EIAG utilization (r s = 0.304, 
P = 0.008). EIAG dosing was utilized in 45, 61.5, 81.8, and 100 % of hospitals with <100, 100–
200, 501–800, and >800 beds, respectively. 
Twenty-seven of the 28 practitioners who stated that their hospitals did not use EIAG provided a 
rationale for why EIAG was not utilized. Nearly 60 % of hospitals stated that a lack of data 
supporting the efficacy of EIAG in children was the reason for not utilizing the dosing strategy. 
Other reasons cited by at least 15 % of hospitals were concern regarding the duration of the drug-
free period (40.7 %), concern regarding the possibility of increased ototoxicity (18.5 %), concern 
regarding the possibility of poorer clinical outcomes (14.8 %), and lack of overall safety data (14.8 
%). Aminoglycoside dosing practices and reasons for not using EIAG are summarized in Table 2. 
Table 2  
Extended-interval aminoglycoside (EIAG) dosing 
  n (%) 
Dosing description 
 Initial tobramycin and gentamicin therapy [n = 41] 
  <3 mg/kg/dose 3 (7.3) 
  3–5 mg/kg/dose 2 (4.9) 
  >5 mg/kg/dose 25 (61) 
  Other 11 (26.8) 
 Target tobramycin and gentamicin peak concentration [n = 42] 
  ≤10 µg/mL 8 (19) 
  11–14 µg/mL 6 (14.3) 
  15–19 µg/mL 6 (14.3) 
  ≥20 µg/mL 22 (52.4) 
Reasons cited for not utilizing EIAG [n = 27] 
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  n (%) 
 Lack of data supporting efficacy of EIAG dosing 15 (55.6) 
 Concern about duration of drug-free period 11 (40.7) 
 Concern about possibility of increased ototoxicity 5 (18.5) 
 Concern about possibility of poorer clinical outcomes 4 (14.8) 
 Lack of overall safety data 4 (14.8) 
 Lack of data regarding incidence of ototoxicity 3 (11.1) 
 Concern about therapeutic drug monitoring 3 (11.1) 
 Lack of data regarding incidence of nephrotoxicity 2 (7.4) 
 Concern about possibility of increased nephrotoxicity 2 (7.4) 
 Lack of drug resistance within hospital 1 (3.7) 
 
3.2 Extended- and Continuous-Infusion β-Lactam Dosing 
Sixty-seven practitioners (87 %) responded when asked if EIBL dosing was utilized in their 
hospitals. Of these, 16 (23.9 %) stated that EIBL was used in their hospitals, with EIPT being most 
common at 93.8 % utilization, followed by extended-infusion meropenem (68.8 %) and cefepime 
(31.3 %). EIBL dosing was reported as being used in most and in some patients in 18.8 and 81.2 
% of hospitals, respectively. There was a fair positive relationship between EIBL and ASP FTE 
≥1 (r s = 0.228). Hospitals in the Eastern US regions use EIBL significantly more frequently than 
those in the Midwest/West (40 versus 10.8 %, P = 0.009). No other associations were observed. 
The most common reasons for not utilizing EIBL were a lack of efficacy data in pediatrics and 
concern about requiring more intravenous access, both of which were cited by 54.5 % of 
practitioners. Other reasons can be found in Table 3. 
Table 3  
Stated rationales for not utilizing extended-interval β-lactam (EIBL) and continuous-infusion β-
lactam (CIBL) 
  n (%) 
Reasons cited for not utilizing EIBL [n = 67] 
 Lack of efficacy data in pediatric patients 36 (53.7) 
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  n (%) 
 Concern about requiring more intravenous access sites 36 (53.7) 
 Concern about compatibility with other administered drugs 26 (38.8) 
 Concern about prolonged use of intravenous access 21 (31.3) 
 Lack of drug resistance within hospital 17 (25.4) 
 Lack of safety data in pediatric patients 12 (17.9) 
 Concern about possibility of inappropriate dosing when switching to extended-interval 
dosing 7 (10.4) 
 Concern about drug stability 6 (9) 
Reasons cited for not utilizing CIBL [n = 64] 
 Concern about requiring more intravenous access sites 23 (35.9) 
 Concern about prolonged use of intravenous access 35 (54.7) 
 Concern about compatibility with other administered drugs 8 (12.5) 
 Lack of efficacy data in pediatric patients 11 (17.2) 
 Lack of drug resistance within hospital 13 (20.3) 
 Lack of safety data in pediatric patients 9 (14.1) 
 Concern about drug stability 26 (40.6) 
 Concern about possibility of inappropriate dosing when switching to extended-interval 
dosing 
13 
(20.3) 
 
Sixty-three responding practitioners provided information about using CIBL, and eight of these 
(12.7 %) reported CIBL being used in their hospitals. Of the respondents who indicated CIBL use, 
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all utilize continuous-infusion (CI) nafcillin, 62.5 % (5/8) utilize CI penicillin, and 12.5 % (1/8) 
utilize CI oxacillin. The reasons provided for not using CIBL are summarized in Table 3, with the 
most common being concern about requiring more intravenous access sites, at 54.7 %. No 
significant relationships between utilizing CIBL and any other variables were observed. 
4 Discussion 
With the increasing prevalence of bacterial resistance, and the associated negative outcomes, 
antimicrobial dosing strategies incorporating fundamental pharmacokinetic–pharmacodynamic 
principles that aim to optimize the drugs’ efficacy should be considered [1, 2, 17]. This is 
especially important in children where, because of clinical research limitations, there may be fewer 
novel antimicrobials available for pediatric use than for adult use. Dose optimization also remains 
an important strategy in both adult and pediatric ASP [18, 19]. Pharmacokinetics develop across 
the age spectrum of pediatrics and can make extrapolation of adult literature difficult [20]. 
Age, however, does not alter antimicrobial-specific pharmacodynamic properties. In pediatrics and 
adults, aminoglycosides are concentration dependent, relying on high peak concentrations relative 
to the organism MIC for maximal bacterial killing, and β-lactam antibiotics are time dependent, 
relying on the length of time for which the free antibiotic concentrations remain above the MIC 
for optimal killing [21, 22]. With pharmacodynamics in mind, careful investigation of 
pharmacokinetic development is imperative to fully optimize antimicrobial dosing. With 
increasing bacterial MICs to aminoglycosides, conventional doses may not attain a desired peak 
concentration to optimize the peak:MIC ratio [21, 23]. Given the short half-lives of β-lactam 
antimicrobials in children, traditional infusion times (those of 30 min or less) may have a lower 
probability of target attainment in infections due to bacteria with elevated MICs [13, 14]. 
EIAG, EIBL, and CIBL dosing strategies utilize fundamental pharmacokinetic–pharmacodynamic 
principles and can optimize drug therapy in adults and children [3, 24]. Despite growing reports 
on these strategies in adults, general use in pediatrics is widely unknown. Our findings demonstrate 
that, according to the practitioners’ responses to the survey, nearly two-thirds of US hospitals 
caring for children are utilizing the optimized dosing approach of EIAG, but less than one-quarter 
utilize EIBL or CIBL. 
Traditional aminoglycoside dosing (e.g., tobramycin 2.5 mg/kg given every 8 h) typically fails to 
take advantage of aminoglycosides’ concentration-dependent bactericidal activity and 
postantibiotic effect (PAE) [3, 9]. Extended-interval dosing can optimize the pharmacokinetic–
pharmacodynamic principles but requires larger cumulative doses at an interval of once daily or 
longer (e.g., 4.5–7.5 mg/kg given every 24 h) [3, 9]. In 1993 and 1998, national surveys of 500 
acute care hospitals in the USA were conducted to evaluate the adoption of EIAG. Although only 
19 % of hospitals surveyed had adopted this dosing strategy in adult patients in 1993, 75 % of the 
responding facilities were using EIAG in the adult population by 1998 [16, 25]. Despite this rapid 
increase in EIAG usage in adults, in 1998 only 23 % of respondents used EIAG for pediatric 
patients [16]. Over the 16 years since Chuck and colleagues performed their survey, EIAG use has 
grown modestly, from 23 to 63 %, and there still appear to be hospitals caring for children that do 
not use EIAG. 
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Though this survey cannot determine all barriers to adoption of EIAG, some barrier themes can be 
investigated. Previously published concerns regarding EIAG in pediatric patients include limited 
available data, increased aminoglycoside clearance in children, determination of the most 
appropriate dose, and the overall safety and efficacy of this dosing strategy [3, 9]. The most 
common reason cited for not using EIAG in this survey was a lack of supporting efficacy data, 
which was identified by nearly 60 % of hospitals. Reviews and meta-analyses have summarized 
neonatal and pediatric EIAG efficacy data [8, 9, 26, 27]. Given the available efficacy data, the high 
percentage of respondents describing the lack of supporting efficacy data as a barrier is surprising. 
Perhaps the more important barrier is the lack of direct comparative efficacy relative to 
traditionally dosed aminoglycosides. However, well-designed and adequately powered studies 
directly comparing EIAG with traditionally dosed aminoglycosides are not likely to be feasible, 
because of cost and subject recruitment considerations. 
Another common concern was related to the duration of the drug-free period, which was a concern 
stated by 40.7 % of hospitals. This is a similar concern to those discussed in other reports, but one 
of interest relating to the term “drug-free” [9]. This likely has more to do with the unknown 
duration of the PAE, which can be impacted by factors such as the infecting bacteria and the initial 
serum concentration, and the potential for bacterial regrowth following the end of the PAE [9, 28, 
29]. Clinically, the precise duration of the aminoglycoside PAE may not be known, but it is 
unlikely that an aminoglycoside would be used as monotherapy. The available EIAG efficacy data 
in children suggest, despite the unknown PAE duration, that EIAG is an effective dosing strategy. 
This could be more of a perceived barrier than an actual barrier and is related, to some degree, to 
the concern about efficacy data. This barrier could be overcome by focused efforts with education 
on the available EIAG efficacy data. 
There were fewer safety-related reasons for not adopting EIAG. Reasons related to ototoxicity and 
nephrotoxicity were cited in fewer hospitals than efficacy concerns, with 30 and 15 % of hospitals, 
respectively, reporting these concerns. The challenge for pediatric practitioners is balancing those 
concerns with the potential benefits of providing an optimized aminoglycoside dose. A solution 
would be to increase hospital education efforts, which, along with dose optimization, is a 
supplemental ASP strategy to increase awareness of the existing literature and fundamental drug 
knowledge among practitioners using aminoglycosides [18, 19]. This might be especially 
important in smaller hospitals, where there appears to be a negative relationship with EIAG use. 
Fewer than 25 % of hospitals utilized EIBL or CIBL. With both of these dosing strategies, concerns 
related to intravenous access or need for additional intravenous access were most common and 
were reported by at least 40 % of hospitals. These are valid concerns, given the challenge of 
obtaining and maintaining intravenous access in pediatrics. Nichols and colleagues [10] 
demonstrated the feasibility of using EIPT in a pediatric cohort without the need for additional 
intravenous access. The presence of these feasibility data could be one explanation for why most 
hospitals in our survey utilize EIPT over meropenem or cefepime with respect to the concern about 
intravenous access. It is possible that these reasons may present more of a perceived barrier to the 
use of these dosing strategies, rather than an actual barrier. If each patient were evaluated as an 
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individual case, considering other medications to be administered and the state of the patient’s 
intravenous access, it might be possible to implement these dosing strategies more frequently. 
Efficacy concerns about EIBL were also cited (53.7 %) as reasons why this dosing strategy is not 
utilized. While adult data have demonstrated efficacy and positive patient outcomes with EIPT, 
similar pediatric data are lacking [4–6]. Courter and Cies [13, 14] both demonstrated higher 
probability of target attainment with EIBL regimens, but did not report patient outcomes data. 
Tamma and colleagues [17] demonstrated a nearly 25 % 30-day mortality rate in children with 
bacteremia due to Pseudomonas aerugonisa isolates with elevated piperacillin MICs. Bacteremia 
due to Pseudomonas aerugonisa isolates with a piperacillin MIC ≥32 µg/mL was associated with 
increased mortality compared with bacteremia due to more susceptible isolates. Courter and Cies 
[13, 14] each demonstrated less than 20 % probability of target attainment when using commonly 
recommended piperacillin doses administered over a 30-min infusion for Pseudomonas 
aerugonisa isolates with MICs ≥32 µg/mL. Considering this along with Tamma’s data [17], it is 
reasonable to posit that EIBL regimens could positively benefit patient outcomes. Despite the lack 
of similar data summarizing the impact of elevated cefepime and carbapenem MICs on pediatric 
clinical outcomes, it is also reasonable to suspect similar negative clinical outcomes with respect 
to those antimicrobials. Because the time from obtaining a specimen for culture until availability 
of susceptibility data can be days, it is critical to optimize β-lactam dosing at therapy initiation. 
Delaying this optimization potentially increases the risk of poor clinical outcomes and, in some 
cases, waiting may just create too much delay. This observation underscores the global need for 
additional research to document the efficacy of these dosing strategies in pediatric patients. For 
both EIBL and CIBL, concerns regarding inappropriate dosing when switching to one of these 
regimens were reported by at least 10 % of hospitals. Development of order guidance forms, 
specifically with EIBL and CIBL dosing regimens included, would be one solution for addressing 
this concern. 
The limitations of our survey and the generalizability of its findings include a lower response rate, 
which introduces the potential for non-response bias. A small sample of respondents could limit 
the interpretation of any significant relationships between tested parameters and dosing strategies. 
Our survey used all CHA hospitals as the target population. Considering the comparable 
distribution of hospital sizes, types, and US locations of the hospitals responding to our survey, a 
sampling of 36 %, which was our survey response rate, does appear to be a representative sample 
of the target population. In order to develop a survey that practitioners would be able to complete 
in a timely manner, the survey was able to query only basic information regarding the use of these 
dosing strategies at the target hospitals. How the dosing strategies are being used in institutions, 
such as whether they are used only in cystic fibrosis exacerbations or for organisms with elevated 
MICs, was not examined, which may limit some of the generalizability of the findings. More 
detailed information could be obtained from a larger survey, but that could further decrease the 
response rate. Lastly, our findings are based on the response from a single representative from the 
hospital. It is reasonable to think that there could be some variability in response if multiple 
practitioners from the hospital completed the survey. 
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Our survey indicates that EIAG dosing strategies have become increasingly adopted in pediatric 
patients but are still only utilized in just over 60 % of hospitals caring for children. There remains 
room for improvement in both the utilization of, and education on, existing pediatric data. Dosing 
strategies to optimize the pharmacokinetic–pharmacodynamic principles of β-lactam 
antimicrobials, including EIBL and CIBL, are used with much lesser frequency in 25 % of 
hospitals. Further study into EIBL and CIBL will provide valuable data that can be used to support 
increased adoption of these dosing strategies in children. Focused education efforts, along with 
ongoing ASP strategies, where present, remain important in the pursuit of optimizing pediatric 
antimicrobial dosing. 
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